Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan.

Ohtsu Y, Matsumaru T, Katashima M, Kakehi M, Kakuo H, Suzuki T, Mabuchi M, Nakamura R, Nakamura T, Katori N, Tanaka S, Saito Y.

Bioanalysis. 2018 Nov 26. doi: 10.4155/bio-2018-0257. [Epub ahead of print] No abstract available.

PMID:
30475072
2.

An Open-Label, Single-Dose, Human Mass Balance Study of Amenamevir in Healthy Male Adults.

Kato K, den Adel M, Groenendaal-van de Meent D, Ohtsu Y, Takada A, Katashima M.

Clin Pharmacol Drug Dev. 2018 Nov 9. doi: 10.1002/cpdd.630. [Epub ahead of print]

PMID:
30412362
3.

Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects.

Shibata T, Nomura Y, Takada A, Aoki S, Katashima M, Murakami H.

J Clin Pharm Ther. 2018 Oct;43(5):633-639. doi: 10.1111/jcpt.12729. Epub 2018 Jul 7.

PMID:
29981285
4.

Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.

Shibata T, Nomura Y, Takada A, Ueno M, Katashima M, Yazawa R, Furihata K.

Clin Pharmacol Drug Dev. 2018 Jul 2. doi: 10.1002/cpdd.597. [Epub ahead of print]

PMID:
29966038
5.

Effects of catechin-enriched ion beverage intake on thermoregulatory function in a hot environment.

Nishimura R, Nishimura N, Iwase S, Takeshita M, Katashima M, Katsuragi Y, Sato M.

J Physiol Sci. 2018 Apr 23. doi: 10.1007/s12576-018-0615-7. [Epub ahead of print]

PMID:
29687331
6.

A phase I, open-label, single-dose micro tracer mass balance study of 14C-labeled ASP7991 in healthy Japanese male subjects using accelerator mass spectrometry.

Miyatake D, Nakada N, Takada A, Kato K, Taniuchi Y, Katashima M, Sawamoto T.

Drug Metab Pharmacokinet. 2018 Apr;33(2):118-124. doi: 10.1016/j.dmpk.2018.03.001. Epub 2018 Mar 7.

PMID:
29606543
7.

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.

Kusawake T, Kowalski D, Takada A, Kato K, Katashima M, Keirns JJ, Lewand M, Lasseter KC, Marbury TC, Preston RA.

Adv Ther. 2017 Dec;34(12):2612-2624. doi: 10.1007/s12325-017-0643-3. Epub 2017 Nov 13.

8.

Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies.

Kusawake T, Keirns JJ, Kowalski D, den Adel M, Groenendaal-van de Meent D, Takada A, Ohtsu Y, Katashima M.

Adv Ther. 2017 Dec;34(12):2625-2637. doi: 10.1007/s12325-017-0642-4. Epub 2017 Nov 13.

9.

Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.

Kusawake T, den Adel M, Groenendaal-van de Meent D, Garcia-Hernandez A, Takada A, Kato K, Ohtsu Y, Katashima M.

Adv Ther. 2017 Nov;34(11):2466-2480. doi: 10.1007/s12325-017-0634-4. Epub 2017 Oct 26.

10.
11.

Effect of shortened sleep on energy expenditure, core body temperature, and appetite: a human randomised crossover trial.

Hibi M, Kubota C, Mizuno T, Aritake S, Mitsui Y, Katashima M, Uchida S.

Sci Rep. 2017 Jan 10;7:39640. doi: 10.1038/srep39640.

12.

Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females.

Nomura Y, Iitsuka H, Toyoshima J, Kuroishi K, Hatta T, Kaibara A, Katashima M, Moy S, Sawamoto T.

Drug Metab Pharmacokinet. 2016 Dec;31(6):411-416. doi: 10.1016/j.dmpk.2016.08.002. Epub 2016 Aug 18.

PMID:
27829538
13.

Integrative pharmacokinetic-pharmacodynamic modeling and simulation of amenamevir (ASP2151) for treatment of recurrent genital herpes.

Takada A, Katashima M, Kaibara A, Chono K, Katsumata K, Sawamoto T, Suzuki H, Yano Y.

Drug Metab Pharmacokinet. 2016 Aug;31(4):323-32. doi: 10.1016/j.dmpk.2016.05.005. Epub 2016 Jun 10.

PMID:
27461507
14.

[Pharmacological and clinical profile of nitisinone (Orfadin(®) Capsules): a therapeutic agent for hereditary tyrosinemia type 1].

Minoura H, Iwai M, Taniuchi Y, Katashima M, Takahashi H.

Nihon Yakurigaku Zasshi. 2015 Dec;146(6):342-8. doi: 10.1254/fpj.146.342. Japanese. No abstract available.

PMID:
26657126
15.

Japanese bioanalytical method validation guideline: the world's first regulatory guideline dedicated to ligand-binding assays.

Imazato-Hirano M, Taniguchi Y, Kakehi M, Kuze Y, Nakamura T, Minamide Y, Miya K, Hosogi J, Katashima M, Maekawa K, Okuda H, Niimi S, Kawasaki N, Ishii-Watabe A, Katori N.

Bioanalysis. 2015;7(9):1151-6. doi: 10.4155/bio.15.43. No abstract available.

PMID:
26039811
16.

Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects.

Iitsuka H, van Gelderen M, Katashima M, Takusagawa S, Sawamoto T.

Clin Ther. 2015 May 1;37(5):1031-44. doi: 10.1016/j.clinthera.2015.02.021. Epub 2015 Mar 16.

17.

Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes.

Takada A, Katashima M, Kaibara A, Sawamoto T, Zhang W, Keirns J.

Clin Pharmacol Drug Dev. 2014 Sep;3(5):365-70. doi: 10.1002/cpdd.108. Epub 2014 Feb 17.

PMID:
27129009
18.

[Impact of visceral fat measurements and a weight loss support web system on visceral fat loss in a workplace setting: insights from a JVALUE2 (Japanese study of visceral adiposity and lifestyle information; utilization and evaluation)].

Okazaki H, Dohi S, Ide H, Murata A, Muramatsu G, Ito D, Sakane N, Morimoto T, Uchida T, Katashima M, Yanagisawa Y, Yasumasu T.

Sangyo Eiseigaku Zasshi. 2014;56(5):109-15. Epub 2014 Jul 18. Japanese.

19.

Effects of Visceral Fat Accumulation Awareness on a Web-Based Weight-Loss Program: Japanese Study of Visceral Adiposity and Lifestyle Information-Utilization and Evaluation (J-VALUE).

Sakane N, Dohi S, Sakata K, Hagiwara S, Morimoto T, Uchida T, Katashima M, Yanagisawa Y, Yasumasu T, Study Group JV.

ISRN Obes. 2013 Apr 24;2013:473764. doi: 10.1155/2013/473764. eCollection 2013.

20.

Association of dietary factors with abdominal subcutaneous and visceral adiposity in Japanese men.

Kondoh T, Takase H, Yamaguchi TF, Ochiai R, Katashima M, Katsuragi Y, Sakane N.

Obes Res Clin Pract. 2014 Jan-Feb;8(1):e16-25. doi: 10.1016/j.orcp.2012.07.005.

PMID:
24548573
21.

Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.

Iitsuka H, Tokuno T, Amada Y, Matsushima H, Katashima M, Sawamoto T, Takusagawa S, van Gelderen M, Tanaka T, Miyahara H.

Clin Drug Investig. 2014 Jan;34(1):27-35. doi: 10.1007/s40261-013-0146-1.

22.

Imaging and estimation of human abdominal fat by electrical impedance tomography using multiple voltage measurement patterns.

Yamaguchi TF, Katashima M, Wang LQ, Kuriki S.

Conf Proc IEEE Eng Med Biol Soc. 2013;2013:3299-302. doi: 10.1109/EMBC.2013.6610246.

PMID:
24110433
23.

Nighttime snacking reduces whole body fat oxidation and increases LDL cholesterol in healthy young women.

Hibi M, Masumoto A, Naito Y, Kiuchi K, Yoshimoto Y, Matsumoto M, Katashima M, Oka J, Ikemoto S.

Am J Physiol Regul Integr Comp Physiol. 2013 Jan 15;304(2):R94-R101. doi: 10.1152/ajpregu.00115.2012. Epub 2012 Nov 21.

24.

Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or non-Hodgkin lymphoma.

Aoyama Y, Katashima M, Sawamoto T.

Biopharm Drug Dispos. 2013 Mar;34(2):137-40. doi: 10.1002/bdd.1827. Epub 2012 Dec 28.

PMID:
23138529
25.

Positive natural selection of TRIB2, a novel gene that influences visceral fat accumulation, in East Asia.

Nakayama K, Ogawa A, Miyashita H, Tabara Y, Igase M, Kohara K, Miki T, Kagawa Y, Yanagisawa Y, Katashima M, Onda T, Okada K, Fukushima S, Iwamoto S.

Hum Genet. 2013 Feb;132(2):201-17. doi: 10.1007/s00439-012-1240-9. Epub 2012 Oct 31.

PMID:
23108367
26.

Visceral fat area, waist circumference and metabolic risk factors in abdominally obese Chinese adults.

Li X, Katashima M, Yasumasu T, Li KJ.

Biomed Environ Sci. 2012 Apr;25(2):141-8.

27.
28.

Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment.

Aoyama Y, Nishimura T, Sawamoto T, Satoh T, Katashima M, Nakagawa K.

Cancer Chemother Pharmacol. 2012 Sep;70(3):373-80. doi: 10.1007/s00280-012-1913-z. Epub 2012 Jul 18.

29.

The short-term effect of diacylglycerol oil consumption on total and dietary fat utilization in overweight women.

Hibi M, Sugiura Y, Yokoyama R, Takase H, Shiiba D, Meguro S, Katashima M, Shimizu A, Tokimitsu I.

Obesity (Silver Spring). 2011 Mar;19(3):536-40. doi: 10.1038/oby.2010.173. Epub 2010 Sep 2.

30.

Practical human abdominal fat imaging utilizing electrical impedance tomography.

Yamaguchi T, Maki K, Katashima M.

Physiol Meas. 2010 Jul;31(7):963-78. doi: 10.1088/0967-3334/31/7/007. Epub 2010 Jun 15.

PMID:
20551507
31.

Role of micafungin in the antifungal armamentarium.

Ikeda F, Tanaka S, Ohki H, Matsumoto S, Maki K, Katashima M, Barrett D, Aoki Y.

Curr Med Chem. 2007;14(11):1263-75. Review.

PMID:
17504145
32.

Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections.

Tabata K, Katashima M, Kawamura A, Kaibara A, Tanigawara Y.

Drug Metab Pharmacokinet. 2006 Aug;21(4):324-31.

33.

Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis.

Tabata K, Katashima M, Kawamura A, Kagayama A, Kohno S.

Eur J Drug Metab Pharmacokinet. 2006 Apr-Jun;31(2):123-8.

PMID:
16898081
34.

Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections.

Tabata K, Katashima M, Kawamura A, Tanigawara Y, Sunagawa K.

Biol Pharm Bull. 2006 Aug;29(8):1706-11.

35.

A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance.

Ryo M, Maeda K, Onda T, Katashima M, Okumiya A, Nishida M, Yamaguchi T, Funahashi T, Matsuzawa Y, Nakamura T, Shimomura I.

Diabetes Care. 2005 Feb;28(2):451-3. No abstract available.

PMID:
15677816
36.

Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.

Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, Iga T.

Drug Metab Dispos. 2001 Apr;29(4 Pt 1):443-52.

37.

Analysis of antiplatelet effect of ticlopidine in humans: modeling based on irreversible inhibition of platelet precursors in bone marrow.

Katashima M, Yamada Y, Yamamoto K, Kotaki H, Sato H, Sawada Y, Iga T.

J Pharmacokinet Biopharm. 1999 Jun;27(3):283-96.

PMID:
10728490
38.

Smoking accelerates absorption of inhaled neutrophil elastase inhibitor FK706.

Koizumi F, Murakami M, Kageyama H, Katashima M, Terakawa M, Ohnishi A.

Clin Pharmacol Ther. 1999 Nov;66(5):501-8.

PMID:
10579477
39.

Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.

Katashima M, Yamamoto K, Tokuma Y, Hata T, Sawada Y, Iga T.

Eur J Drug Metab Pharmacokinet. 1998 Jan-Mar;23(1):19-26.

PMID:
9625268
40.

Pharmacokinetics and pharmacodynamics of FK143, a nonsteroidal inhibitor of steroid 5 alpha-reductase, in healthy volunteers.

Katashima M, Irino T, Shimojo F, Kawamura A, Kageyama H, Higashi N, Miyao Y, Tokuma Y, Hata T, Yamamoto K, Sawada Y, Iga T.

Clin Pharmacol Ther. 1998 Mar;63(3):354-66.

PMID:
9542479
41.
43.

Pharmacokinetic analysis of benzodiazepine receptor binding of [123I]iomazenil in human brain.

Ito K, Momose T, Kotaki H, Kojima Y, Yamamoto K, Katashima M, Sawada Y, Sasaki Y, Iga T.

Pharm Res. 1997 Aug;14(8):999-1003.

PMID:
9279879
44.

Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.

Katashima M, Yamamoto K, Sugiura M, Sawada Y, Iga T.

Drug Metab Dispos. 1995 Jul;23(7):718-23.

PMID:
7587960
45.

Perinatal development of amine, alcohol and phenol sulfoconjugations in the rat.

Iwasaki K, Shiraga T, Takeshita K, Katashima M, Nagase K, Tada K, Noda K, Noguchi H.

Res Commun Chem Pathol Pharmacol. 1993 Aug;81(2):183-90.

PMID:
8210697
46.

[Urinary excretion of fentanyl and its metabolites at high-dose infusion].

Goromaru T, Kawauchi T, Katashima M, Matsuura H, Yoshimura N, Sameshima T, Miyawaki T.

Masui. 1986 Jan;35(1):35-9. Japanese. No abstract available.

PMID:
3712731
47.

Metabolism of fentanyl in isolated hepatocytes from rat and guinea pig.

Goromaru T, Katashima M, Matsuura H, Yoshimura N.

Chem Pharm Bull (Tokyo). 1985 Sep;33(9):3922-8. No abstract available.

PMID:
4092292

Supplemental Content

Loading ...
Support Center